Heung Jae Kim Selected Research

4- (3- amino- 4- (2,4,5- trifluorophenyl)butanoyl)- 3- (tert- butoxymethyl)piperazin- 2- one

12/2017	Unique binding mode of Evogliptin with human dipeptidyl peptidase IV.
1/2012	DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes.
6/2011	Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Heung Jae Kim Research Topics

Disease

2	Inflammation (Inflammations) 09/2019 - 01/2016
2	Type 2 Diabetes Mellitus (MODY) 12/2017 - 06/2011
1	Atopic Dermatitis (Atopic Eczema) 09/2019
1	Pruritus (Itching) 09/2019
1	Systemic Scleroderma (Systemic Sclerosis) 07/2016
1	Pneumonia (Pneumonitis) 01/2016
1	Glucose Intolerance 01/2012
1	Insulin Resistance 01/2012
1	Body Weight (Weight, Body) 01/2012

Drug/Important Bio-Agent (IBA)

3	4- (3- amino- 4- (2,4,5- trifluorophenyl)butanoyl)- 3- (tert- butoxymethyl)piperazin- 2- oneIBA 12/2017 - 06/2011
2	Peptides (Polypeptides)IBA 09/2019 - 07/2016
1	PTPD-12IBA 09/2019
1	Immunoglobulin A (IgA)IBA 09/2019
1	PiperazineIBA 12/2017
1	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 12/2017
1	Type I DNA Topoisomerases (Topoisomerase I)IBA 07/2016
1	Amino Acids FDA Link 07/2016
1	HLA-DPB1 antigen (HLA DPB1)IBA 07/2016
1	Peroxidase (Myeloperoxidase)IBA 01/2016
1	SmokeIBA 01/2016
1	LipopolysaccharidesIBA 01/2016
1	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2012
1	AmidesIBA 06/2011